AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ERYTECH Pharma S.A.

Declaration of Voting Results & Voting Rights Announcements Nov 5, 2018

1295_dva_2018-11-05_92692ab5-fc16-48f3-9069-e2cee5712a4f.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France

Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com

Date Total of shares composing
the share capital
Total of brut(1) voting
rights
Total of net(2) voting
rights
December 31, 2017 17 937 559(3) 19 545 443 19 542 943
January 1, 2018 17 940 035(3) 19 543 919(3) 19 541 419
February 28, 2018 17 940 035 19 546 219 19 543 719
March 31, 2018 17 940 035 19 546 221 19 543 721
April 30, 2018 17 940 035 19 554 221 19 551 721
May 31, 2018 17 940 035 19 543 991 19 541 491
June 30, 2018 17 940 035 19 525 991 19 523 491
July 31, 2018 17 940 035 19 525 991 19 523 491
August 31, 2018 17 940 035 19 525 991 19 523 491
September 30, 2018 17 940 035 19 525 741 19 523 241
October 31, 2018 17 940 035 19 525 741 19 523 241

(1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2) Without treasury shares

(3) The number of shares and voting rights increased due to issuance of shares consequently to warrants exercises and or end of vesting periods of free shares which a Board of Director will take notice of in the future.

Talk to a Data Expert

Have a question? We'll get back to you promptly.